Sitagliptin/Metformin 50/850 mg (Sitagliptin Phosphate, Metformin Hydrochloride)
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
MFDS item code 201503172 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is suitable for patients with type 2 diabetes who are using sitagliptin and metformin together. It helps effectively control blood sugar levels, and better effects can be expected when combined with a dietary regimen and exercise therapy. In other words, it is used as an adjunct to improve blood sugar control.
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, section 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 2. Patients in whom this drug is contraindicated).
This medication contains both sitagliptin and metformin and is used for the treatment of type 2 diabetes. First, sitagliptin may rarely cause serious allergic reactions; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, you should immediately stop taking the medication and seek medical attention. Also, there is a risk of pancreatitis, which is inflammation of the pancreas, so if sudden abdominal pain, vomiting, or nausea occurs, it should be reported to medical personnel immediately. Metformin can cause lactic acidosis, a rare but serious metabolic disorder. Symptoms can include muscle pain, fatigue, difficulty breathing, abdominal pain, and confusion. If these symptoms occur, you should stop taking the medication immediately and visit a hospital. This medication should not be administered to patients with moderate to severe renal impairment, severe infection, dehydration, heart failure, or acute myocardial infarction. Additionally, it is essential to stop taking this medication before any tests using radiological contrast agents, and to resume only after confirming that kidney function is normal following the test. It is advisable not to use this medication in pregnant or lactating individuals, or in children under 18 years of age, as safety has not been established. During the course of taking this medication, regular monitoring of kidney function and blood tests should be conducted to check for abnormalities, and periodic checks of vitamin B12 levels are recommended. Moreover, when taking this medication alongside insulin or sulfonylurea medications, the risk of hypoglycemia may increase, so blood sugar levels should be monitored closely. If surgery is planned, this medication should be stopped 48 hours before the surgery, and should only be resumed after oral intake has returned following surgery and kidney function has been confirmed as normal. Finally, excessive alcohol consumption should be avoided while taking this medication, and if any unusual symptoms or discomfort occur during the course of treatment, medical personnel should be consulted immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is not exposed to air, and it is best stored at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication and prevent deterioration.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.